Ionis Pharmaceuticals (NasdaqGS:IONS) FY Conference March 02, 2026 10:30 AM ET Company ParticipantsBrett Monia - CEOConference Call ParticipantsYaron Werber - AnalystYaron WerberOkay. Well, good morning, everybody, and thank you for joining us for the 46th annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team, and it's really a great pleasure to moderate the next fireside chat with Brett Monia, Chief Executive Officer of Ionis. Brett, good to see you.Brett MoniaGood to see you, Yaron ...

Core Viewpoint - Recently, Huaron (Tianjin) Biotechnology Co., Ltd. was established with a registered capital of 10 million RMB, fully owned by Luoyang Huaron Biotechnology Co., Ltd. [1] Company Overview - The legal representative of Huaron (Tianjin) Biotechnology Co., Ltd. is Wei Qunming [1] - The company is classified under the scientific research and technical service industry, specifically in engineering and technical research and development [1] - The registered address is located in the Tianjin Free Trade Zone, specifically at the intersection of Central Avenue and East Fifth Road [1] Shareholding Structure - Luoyang Huaron Biotechnology Co., Ltd. holds 100% of the shares in Huaron (Tianjin) Biotechnology Co., Ltd. [1] Business Scope - The business scope includes various technical services such as technology development, consulting, and transfer, as well as research and development in industrial enzyme preparations, fermentation process optimization, biochemistry products, biopesticides, and biological feed [1] - Additional areas of focus include cell technology research and application, medical research, information technology consulting, and the extraction, purification, and synthesis of marine biological active substances [1]

Core Viewpoint - Shanghai Baoji Pharmaceutical Co., Ltd. officially listed on the Hong Kong Stock Exchange on December 10, with an initial offering price of HKD 26.38 per share, opening at HKD 60.5, a surge of 129% [1][3] Group 1: Company Overview - Baoji Pharmaceutical is a biotechnology company established in 2019, focusing on four strategic areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [5] - The company has a pipeline of 12 self-developed products, including three core products: KJ017, KJ103, and SJ02 (Sheng Nuwa®), along with four other clinical candidates and five preclinical assets [5] Group 2: Financial Performance - The company completed six rounds of financing from September 2020 to December 2024, raising a total of RMB 1.86645 billion, with the last round post-money valuation reaching RMB 4.87 billion [3][4] - For the fiscal years 2023, 2024, and the first half of 2025, the company's revenues were RMB 6.93 million, RMB 6.16 million, and RMB 4.199 million, respectively, with corresponding R&D expenditures of RMB 133 million, RMB 251 million, and RMB 111 million [6][7] Group 3: Market Potential - According to Frost & Sullivan, the clinical addressable market size for the four strategic therapeutic areas in China is expected to reach approximately RMB 50 billion by 2033 [6] - The market for large-volume subcutaneous delivery, particularly recombinant hyaluronidase, is projected to account for nearly RMB 7 billion, while the market for antibody-mediated autoimmune diseases is driven by IgG-related autoimmune diseases, estimated at RMB 26.7 billion [6] Group 4: Use of IPO Proceeds - The company plans to use the funds raised from the IPO for the R&D and commercialization of core products (including KJ017, KJ103, and SJ02), advancing existing pipeline products, optimizing proprietary synthetic biology technology, and enhancing production capacity [7]